The Role of Downstream Kynurenine Pathway Metabolites in the Modulation of Cardiovascular Disease Development in...

Area of Science:

• Nephrology
• Cardiology
• Metabolomics

Background:

• Cardiovascular diseases (CVDs) are the leading cause of mortality in patients with chronic kidney disease (CKD).
• The pathogenesis of CVD in CKD is multifactorial, involving complex metabolic alterations.
• Emerging evidence implicates the kynurenine pathway (KP), a major tryptophan metabolism route, in CKD-associated CVD.

Purpose of the Study:

• To review the current understanding of individual kynurenine (KYN) pathway metabolites' roles in CVD development within the CKD population.
• To synthesize data on KYN metabolites in general CVD and experimental models where CKD-specific data are limited.

Main Methods:

• Literature review synthesizing existing research on kynurenine pathway metabolites and cardiovascular disease.
• Analysis of data from CKD patients, the general population, and experimental models.

Main Results:

• Accumulation of certain KP metabolites (e.g., 3-hydroxykynurenine, quinolinic acid) is linked to CVD risk factors in CKD.
• Other metabolites (e.g., kynurenic acid) may have complex or potentially protective cardiovascular effects.
• Data synthesis includes findings from general populations and experimental models to supplement CKD-specific information.

Conclusions:

• Disturbances in the kynurenine pathway are increasingly recognized as a significant contributor to cardiovascular risk in chronic kidney disease.
• Specific downstream metabolites of the kynurenine pathway exhibit varied associations with cardiovascular disease, necessitating further investigation.
• Understanding these metabolic roles is crucial for developing targeted therapeutic strategies for cardiovascular complications in CKD.